Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

Summary

The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients with a documented M184V mutation.

Timeline

Start

2019-05-22

Primary completion

2022-08

Completion

2022-08-30

Outcome

Outcome not reported

Stopped (Enrollment): “Low recruitment, We did not find participants with the M184V mutation , inclusion criteria , throughout 230 resistance tests carried out”

Drugs

Indications